Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The EPIPEN Act limits what health insurance plans can charge patients for epinephrine delivery systems—devices like auto-injectors, nasal sprays, and sublingual sprays used to treat severe allergic reactions. Under the bill, health plans cannot charge patients more than $60 per package of two delivery systems and cannot impose a deductible for these medications. The law applies to all group health plans and both group and individual health insurance coverage starting January 1, 2026. Patients' out-of-pocket costs for epinephrine will count toward their deductibles and annual out-of-pocket maximums. The bill does not require plans to cover out-of-network epinephrine providers, meaning patients may face higher costs if they use providers outside their plan's network.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.